Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3275 - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: data from the randomized CHIVA trial (a GINECO-GCIG study)


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site

Ovarian Cancer


Patrick Robelin


Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268


P. Robelin1, M. TOD2, O. COLOMBAN1, I.L. Ray-Coquard3, G. De Rauglaudre4, J. Florence5, A. Chevalier6, P. combe7, A. Lortholary8, S. Hamizi9, N. Raban10, G. Ferron11, J. Meunier12, D. Berton-Rigaud13, J. Alexandre14, M. Kaminsky-Forrett15, C. Dubot16, A. Leary17, E. Malaurie18, B. You19

Author affiliations

  • 1 Emr3738, Ciblage Thérapeutique En Oncologie, Faculté De Médecine Et De Maïeutique Lyon-sud Charles Mérieux, Université Claude Bernard Lyon 1, 69921 - OULLINS/FR
  • 2 Pharmacie, Hôpital de la Croix Rousse, Hospices civils de Lyon, 6904 - LYON/FR
  • 3 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 4 Oncologie Radiothérapie, Institut Sainte-Catherine, 84918 - Avignon/FR
  • 5 Calvados, Centre Francois Balesse, 14000 - CAEN/FR
  • 6 Cancerologie Gynecologie, Centre Oscar Lambret, 59020 - Lille/FR
  • 7 Oncologie Medicale, Hopital European George Pompidou, 75015 - Paris/FR
  • 8 Oncologie Médicale, Hôpital Privé du Confluent S.A.S., 44277 - Nantes Cédex/FR
  • 9 Oncologie Medicale, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 10 Pôle Régional De Cancérologie, Service D'oncologie, Hôpital de la Milétrie - CHU de Poitiers, 86021 - Poitiers Cédex/FR
  • 11 Département De Chirurgie Oncologique, Institut Claudius Regaud, 31059 - Toulouse Cédex/FR
  • 12 Service D'oncologie Médicale, Centre Hospitalier Régional d'Orléans, 45067 - Orleans Cédex/FR
  • 13 Oncologie Médicale, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 14 Unité D'oncologie Médicale, Hôpital Cochin, 75014 - PARIS Cédex/FR
  • 15 Oncologie Médicale, ICL Institut de Cancérologie de Lorraine, 54511 - Vandoeuvre-les-Nancy Cédex/FR
  • 16 Oncologie Médicale, Hôpital René Huguenin - Institut Curie, 92210 - St. Cloud/FR
  • 17 Gynecologic Unit, Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), 94805 - Villejuif/FR
  • 18 Oncologie, Radiothérapie, CHI de Créteil, 94010 - Créteil Cédex/FR
  • 19 Oncology, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3275


MicroRNAs (miRNAs) are promising biomarkers in ovarian cancer. Their kinetics during treatment might be useful for monitoring disease burden, and guiding treatments in patients treated with neoadjuvant chemotherapy and interval debulking surgery (IDS).


Serial blood samples of patients enrolled in the randomized phase II CHIVA trial, comparing neo-adjuvant carboplatin-paclitaxel +/- nintedanib (NCT01583322), were investigated to assess the kinetics of 11 relevant miRNAs compared to CA125 kinetics, using C-index & survival tests for predictive and prognostic values. MiRNAs were extracted and quantified by qRT-PCR. The selection of the final 11 miRNAs was based on the expression levels found with a large explorative panel of 84 miRNAs in 8 patients, and on the literature: miR-15b-5p, miR-16-5p, miR-20a-5p, miR-21-5p, miR-93-5p, miR-122-5p, miR-150-5p, miR-195-5p, miR-200b-3p, miR-148b-5p and miR-34a-5p.


756 serial blood samples done every 3 weeks from 119 patients were analyzed for a total of 8172 miRNA assays, and 1299 CA-125 values. About 82% of miRNA concentrations were above the limits of quantification. The time courses of the miRNAs expressions were highly heterogeneous, and were not parallel with the CA-125 time changes. The miRNAs kinetics during treatment were not found associated with disease bulk changes, RECIST tumor response, or cytoreductive surgery outcomes (optimal vs non-optimal IDS). However, for 6 of them (miR-15b-5p; miR-16-5p; miR-20a-5p; miR-21-5p; miR-93-5p; and miR-195-5p), significant increases at disease progressions were found (median 40%). Decreases of miR-34a-5p and miR-93-5p were associated with PFS benefit (13.7 vs 24.8 months; p = 0.009) and OS benefits (34.3 months vs Not reached; p < 0.001), respectively, using univariate tests.


The longitudinal kinetics of miRNA expressions during neo-adjuvant treatment in ovarian cancer patients were inconsistent, and were not found to be associated with tumor burden changes. Although some prognostic value could be discussed, no predictive value regarding tumor responses or IDS quality could be identified.

Clinical trial identification

EudraCT: 2011-006288-23.

Editorial acknowledgement

Legal entity responsible for the study



Boehringer Ingelheim.


I.L. Ray-Coquard: Honoraria (self): AstraZeneca; Honoraria (self): Clovis; Honoraria (self): Tesaro; Honoraria (self): Pharma Mar; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: Clovis; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Genmab; Advisory / Consultancy: pharma Mar; Advisory / Consultancy: MSD; Advisory / Consultancy: Pfizer; Research grant / Funding (institution): MSD; Travel / Accommodation / Expenses: AstraZeneca. J. Florence: Advisory / Consultancy: Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Astellas; Advisory / Consultancy: Bayer; Advisory / Consultancy: BMS; Advisory / Consultancy: Sanofi; Research grant / Funding (institution): BMS; Travel / Accommodation / Expenses: Janssen; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: BMS. A. Lortholary: Honoraria (self): AstraZeneca; Honoraria (self): Tesaro. N. Raban: Travel / Accommodation / Expenses: Roche. G. Ferron: Honoraria (self): Olympus Europe; Advisory / Consultancy: AstraZeneca; Travel / Accommodation / Expenses: Roche. J. Alexandre: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Honoraria (self): Ipsen; Honoraria (self): Novartis; Honoraria (self): PharmaMar; Advisory / Consultancy: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Novartis; Research grant / Funding (institution): Janssen; Travel / Accommodation / Expenses: Janssen; Travel / Accommodation / Expenses: Novartis. A. Leary: Advisory / Consultancy: Tesaro; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Clovis; Advisory / Consultancy: Gamamab; Advisory / Consultancy: Gridstone; Advisory / Consultancy: Seattle Genetics; Travel / Accommodation / Expenses: Clovis; Travel / Accommodation / Expenses: Tesaro; Travel / Accommodation / Expenses: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.